Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896785 | 0.83 | KIF11 (0.64) | KIF11TDP1MAPTMEN1POLB | |
| Hydrochloric Acid SCHEMBL6575263 | 0.79 | KIF11 (0.50) | KIF11TDP1MAPTMEN1POLB | |
| SCHEMBL3896158 | 0.79 | KIF11 (0.72) | KIF11 | |
| SCHEMBL2380887 | 0.78 | TDP1 (0.63) | KIF11TDP1MAPTMEN1POLB | |
| SCHEMBL29267940 | 0.78 | ALDH1A1 (0.49) | KIF11TDP1MAPTMEN1POLB | |
| SCHEMBL5531408 | 0.78 | KIF11 (0.72) | KIF11 | |
| SCHEMBL28279522 | 0.77 | KIF11 (0.60) | KIF11TDP1MAPTMEN1POLB | |
| SCHEMBL25247338 | 0.76 | TDP1 (0.76) | TDP1MAPTMEN1POLBKMT2A | |
| SCHEMBL31109079 | 0.76 | TDP1 (0.76) | TDP1MAPTMEN1POLBKMT2A | |
| SCHEMBL416825 | 0.76 | MAPT (0.76) | TDP1MAPTMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885TDP1 918/4885MAPT 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.